Print this page
breast
-
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-Label Phase 3 Study.
Protocol: 042410Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants with HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer.
Protocol: 042412Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-Term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Protocol: 051804Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Any Site -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Any Site
Liver
Other Digestive Organ -
A Phase IA/IB, Open Label, Multicenter, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Protocol: 052212Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies.
Protocol: 052401Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Multicenter, Open-label, Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors.
Protocol: 052402Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients with Advanced Solid Tumors.
Protocol: 052404Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase Ia/Ib, Open-Label, Multicenter study to evaluate the Safety, Pharmacokinetics, and activity of Ro7759065 as a single agent and in combination with ATEZOLIZUMAB in Patients with locally advanced or metastatic solid tumors
Protocol: 052406Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR).
Protocol: 052407Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and
Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.
Protocol: 052410Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies.
Protocol: 072014Applicable Disease Sites: Any Site
-
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Liver -
Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.
Protocol: 072202Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Rectum -
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial (PREVENT): Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy.
Protocol: 072212Principal Investigator:
- Henry Richard Alexander
Applicable Disease Sites: Any Site -
Sequential Combined TAS-102 and Oxaliplatin Alternating with TAS-102 and Irinotecan (Sequential TASOXIRI) with Bevacizumab for Late-Line Metastatic Colorectal Cancer.
Protocol: 072303Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon